Millendo Therapeutics Return on Equity

Millendo Therapeutics (MLND) currently reports a ROE of -52.43%. That is below the Healthcare sector average of 29.03%. Use the charts on this page to explore Millendo Therapeutics's ROE history and peer comparisons.

Millendo Therapeutics's ROE of -52.43% is lower than the Healthcare sector average of 29.03%. That is roughly 18159.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Millendo Therapeutics's current -52.43% should be judged against Healthcare norms (sector average: 29.03%) and against MLND's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -52.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.03%. From there, open related valuation or income-statement pages for Millendo Therapeutics, and consider following MLND for alerts when major investors trade the stock.

Millendo Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -52.43% versus a sector average near 29.03%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MLND with unrelated industries.